Bottom line
Is LAVRX a good fund? The bottom line
LAVRX is the Class R3 share class of Lord Abbett Fundamental Equity Fund, a managed large blend mutual fund from Lord Abbett.
It charges 1.18% — about $118 a year on every $10,000 invested, more expensive than 73% of large blend funds we track.
It returned +16.9% over one year, +13.0% a year over five years, +10.6% a year over ten (as of Dec 31, 2025, per its prospectus).
With $2.2 billion in net assets and 57 holdings, its largest position is Alphabet Inc (4.5%) and the top 10 make up 28.1% of the portfolio.
What stands out
- 5-year return beat 75% of category peers
- No front-end sales load
What to watch
- Expensive for its category (1.18%)
- 12b-1 marketing fee of 0.5% a year
Updated Nov 19, 2026
What LAVRX invests in
The Funds investment objective is long-term growth of capital and income without excessive fluctuations in market value.
The Fund invests in equity securities of U.S. and multinational companies across all market capitalization ranges that the portfolio management team believes are undervalued by the market and are selling at reasonable prices in relation to the portfolio management teams assessment of their potential or intrinsic value. Under normal conditions, the Fund invests at least 80% of its net assets, plus the amount of any borrowings for investment purposes, in equity securities. The Fund normally invests at least 50% of its net assets in equity securities of large, established companies having a market capitalization within the range of companies in the Russell 1000 Index. The Fund seeks to invest in securities of companies that the portfolio management team believes are undervalued by the market and are selling at reasonable prices in relation to the portfolio management teams assessment of…
From the fund's prospectus (filed Feb 25, 2026).
LAVRX performance
| 1 yr | 5 yr | 10 yr | |
|---|---|---|---|
| LAVRX | +16.9% | +13.0% | +10.6% |
| Large Blend median | +13.8% | +9.7% | +10.9% |
Source: Fund prospectus, as of Dec 31, 2025
What LAVRX costs
On a $10,000 investment, LAVRX's 1.18% expense ratio costs about $118 a year. The prospectus estimates $1,432 in total costs over 10 years (assuming 5% annual returns). The median large blend fund charges 0.83%.
LAVRX top 10 holdings
| # | Holding | % of fund |
|---|---|---|
| 1 | Alphabet Inc | 4.52% |
| 2 | JPMorgan Chase & Co | 4.05% |
| 3 | Microsoft Corp | 2.90% |
| 4 | Taiwan Semiconductor Manufacturing Co Ltd | 2.58% |
| 5 | UnitedHealth Group Inc | 2.52% |
| 6 | RTX Corp | 2.42% |
| 7 | Wells Fargo & Co | 2.40% |
| 8 | Shell PLC | 2.38% |
| 9 | SEI Investments Co | 2.20% |
| 10 | United Therapeutics Corp | 2.11% |
Source: SEC Form N-PORT, period ended Jul 31, 2026
The top 10 make up 28.1% of the fund. See all top 25 holdings and asset mix →